




FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079CON		SERIAL NO.: 10/033,055	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Ronald BURCH et al.			
				FILING DATE: December 27, 2001		GROUP: 1639	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	AA	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AB						
	AC						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							Yes No
	AD						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AE	Purdue Discovery Research, Department of Neuropharmacology Study Report "Assessment of the Effects of Combined Administration of Oxycodone and Cox II Inhibitors, Celecoxib, Etodolac and Rofecoxib, in the Rat FCA Model of Inflammatory Pain"; July 28, 2003					
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
	AO						
	AP						
	AQ						
	AR						
	AS						
EXAMINER				DATE CONSIDERED 11/4/05			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1079CON

SERIAL NO.: 10/033,055

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Ronald BURCH et al.

FILING DATE: December 27, 2001

GROUP: 1639

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							Yes	No
	AD							

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AE	The Merck Index, 12 th edition, Merck & Co. Publishers, p.1194 (1996)
	AF	Goodman and Gilman's The Pharmacological Basis of Therapeutics, 6 th edition, Macmillan Publishing Co., "Chapter 22: Opioid Analgesics and Antagonists," p.494-497, esp. Tables 22-1, p. 496 (1980)
	AG	Rorarius et al., "Non-steroidal Anti-inflammatory Drugs for Postoperative Pain Relief," Current Opinion in Anesthesiology, 7:358-362 (1994)
	AH	Friedel et al., "Nabumetone- A Reappraisal of its Pharmacology and Therapeutics Use in Rheumatic Diseases," Drugs Vol. 45 (1), pp.131-156 (1993)
	AI	Eversmeyer et al., "Safety Experience With Nabumetone Versus Diclofenac, Naproxen, Ibuprofen, and Piroxicam in Osteoarthritis and Rheumatoid Arthritis, The American Journal of Medicine, Vol. 95 (Suppl. 2A) pp. 10S-18S
	AJ	Tanaka et al., "Pharmacological Studies of the New Antiinflammatory Agent 3-Formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one," Arzneihm-Forsch./Drug res. 42 (II), Nr. 7, pp. 935-944 (1992)
	AK	Engelhardt et al., "Anti-inflammatory, Analgesic, Antipyretic and Related Properties of Meloxicam, a New Non-steroidal Anti-inflammatory Agent with Favorable Gastrointestinal Tolerance," Inflamm. Res. 44:423-433 (1995)
	AL	Engelhardt, "Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2," Brit. J. Rheumatology 1996:35 (suppl. 1): 4-12
	AM	Distel et al., "Safety of Meloxicam: A Global Analysis of Clinical Trials," Brit. J. Rheumatology 1996:35 (suppl. 1):68-77
	AN	Wojtulewski et al., "a Six Month Double-blind Trial to Compare the Efficacy and Safety of Meloxicam 7.5 mg Daily and Naproxen 750 mg Daily in Patients with Rheumatoid Arthritis," Brit. J. Rheumatology 1996:35 (suppl. 1):22-28
	AO	Lipani, "Clinical Update of the Relative Safety of Nabumetone in Long-Term Clinical Trials," Inflammopharmacology (1995) Vol.3(4) pp. 351-361
	AP	Swingle et al., "Predinical Pharmacological Studies With Nimesulide," Drugs Exptl. Clin. Res. Vol. X (8-9) pp. 587-597
	AQ	Rabasseda, "Nimesulide: A Selective Cyclooxygenase 2 inhibitor Antiinflammatory Drug," Drugs of Today Vol 32, No.5 (1996), p9. 365-384
	AR	Siebert et al., "Pharmacological and Biochemical Demonstration of the Role of Cyclooxygenase 2 in Inflammation and Pain," PNAS USA Vol.91 (Dec. 1994) pp. 12013-12-17
	AS	Richardson et al., "The Clinical Implications of Inhibition of the Inducible Form of Cyclo-oxygenase," Drug Safety Vol. 15(4), pp. 249-260 (Oct. 1996)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.